Zimmer Biomet Holdings ZBH
Healthcare · Medical - Devices · Synthos Deep Dive · 2026-07-03
The Overview
Zimmer Biomet makes the artificial knees and hips that surgeons implant when a patient's joints wear out, plus tools and robots for those surgeries. It's a real, profitable business with a strong brand — but it grows slowly, because the number of joint-replacement surgeries only creeps up a few percent a year.
The stock is cheap. You're paying about $10 for every $1 of expected profit — roughly half what you'd pay for a fast-growing medical company. Cheap for a reason: growth has been sluggish and the company carries a fair amount of debt. Our verdict is Buy — Tactical: worth owning as a bargain that could bounce back to fair value, but not the kind of steady grower you buy and forget.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The stock is cheap and doesn't swing wildly with the market, which cushions it — but it owes a good chunk of debt and has already fallen ~50% from its all-time high, so it's not risk-free.
- Growth Quality 4/10 (below average). A solid, mature business, but it barely grows. Fine, not exciting.
- Exponential Potential 2/10 (low). Do not expect this to double from growth. It's a mature company in a slow-growing market; the upside is the price catching back up to fair value.
The one big worry: if joint-replacement growth stays stuck at ~2-3% a year and debt stays high, the stock could stay cheap forever — a "value trap." The buy case needs the market to eventually pay a fairer price for the steady cash it throws off.
Putting a number on it: our fair-value estimate is $108 against a current price of $100.91 — real upside if our numbers are right.
Our summary metrics
Cheap (~10× fwd adj EPS) & low beta 0.47, but 3.1× net-debt/EBITDA and a −50% peak drawdown are real.
Only ~3-4% organic revenue growth, mid-teens ROE/ROIC, margins flat — a slow, mature compounder.
Mature, decelerating orthopedic maker; ~4% revenue CAGR and a $17B cap in a low-growth TAM cap any multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature, decelerating orthopedic maker; ~4% revenue CAGR and a $17B cap in a low-growth TAM cap any multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $96.33 (high $120 / low $83; median $93; 0 Strong Buy · 18 Buy · 21 Hold · 3 Sell → "Hold") — context, not our anchor |
| Valuation | 22.6× trailing GAAP EPS · ~10.3× FY26E · ~9.7× FY27E adj EPS · EV/EBITDA 10.9× · EV/S 2.85× · FCF yield ~8.7% |
| Technicals | Downtrend — $87.47, −19% off 52-wk high, below 200-DMA, RSI 51, −7% 12-mo (SPY +21%) |
| Conviction | Low — 0 net-bullish voices, 0 traceable claims in the Synthos KB; call rests on the quant/value read |
| Position sizing | Satellite value/tactical, ~1–3%, with a hard tripwire on leverage & organic growth |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for ZBH — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $100.91, 7% above the 50-day average ($94), 11% above the 200-day average ($91) — an uptrend. 5% below the 52-week high of $106, 27% above the 52-week low of $80.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $100.91 is currently inside the band (band $96–$102).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 59.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.15, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = ZBH · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Zimmer Biomet (NYSE: ZBH) is a ~100-year-old global medical-device company founded in 1927 and headquartered in Warsaw, Indiana — the historic capital of the orthopedic-implant industry. It designs, makes and sells reconstructive orthopedic products (knee and hip replacements), plus S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial & Thoracic), and a growing suite of surgical robotics, digital and data technologies (ROSA robotic surgery, smart implants). CEO Ivan Tornos; ~17,000 employees. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
- By product category: Knees $3.32B (40%) · S.E.T. $2.15B (26%) · Hips $2.09B (25%) · Technology/Data/Bone-Cement & other ~$0.67B (8%). Knees + hips (core reconstructive) are ~65% of the business.
- By geography: Americas $5.14B (62%) · EMEA $1.83B (22%) · Asia Pacific $1.26B (15%). US-centric, which is a pricing-power strength but also exposes it to US hospital-capital and reimbursement cycles.
The strategic pivot management keeps pushing: shift the mix toward higher-growth adjacencies (S.E.T. grew ~19% in Q1'26, boosted by the April 2025 Paragon 28 foot-and-ankle acquisition) and robotics/AI (ROSA Knee with OptimiZe; the autonomous-robotics Monogram acquisition), to lift a low-single-digit core-recon grower toward a mid-single-digit total.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of ZBH in the Synthos knowledge base. total_claims = 0, breadth = 0, net conviction = 0. None of the tracked, skill-weighted voices in our panel have an on-record, traceable view on Zimmer Biomet.
Per house standard, we do not manufacture conviction to fill the gap. This verdict is entirely fundamentals- and quant-driven — built from the reported financials, the analyst-estimate consensus (labeled as estimates throughout), management's own guidance (half-weighted, §9), and the valuation/technical read below. Treat the conviction rating as Low accordingly: there is no independent expert breadth corroborating the call, only the numbers.
For external context (not Synthos conviction, and not our anchor): the sell-side is lukewarm — 0 Strong Buy, 18 Buy, 21 Hold, 3 Sell, a "Hold" consensus, with a $96.33 average price target. That is a market that sees value but no catalyst — consistent with our own read.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Cheap (~10× fwd adj EPS, ~8.7% FCF yield) and low beta (0.47) cushion the downside, but net-debt/EBITDA 3.1× is elevated and the stock has already drawn down ~50% from its peak — the valuation floor is real but not a fortress. |
| Growth Quality | 4 · Below-average | ~3-4% forward revenue CAGR, ~7% adjusted-EPS CAGR (buyback-aided), ROE ~6% / ROIC ~5% (GAAP, amortization-depressed), flat margins. A durable, mature compounder — not a high-quality grower. |
| Exponential Potential | 2 · Low | Mature orthopedic maker in a low-single-digit-growth category; growth is flat-to-decelerating and a $17B cap in a slow TAM offers no multibagger path. The upside here is re-rating, not exponential growth. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. (EPS below = adjusted/non-GAAP, the basis on which ZBH is quoted and guided; GAAP EPS is far lower due to heavy acquisition amortization — see §5.)
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Robotics/S.E.T. mix-shift + Paragon 28 lift organic growth toward mid-single-digits; margins tick up; buybacks compound. FY27E adj EPS beats to ~$9.5; the multiple re-rates to a still-modest ~14× as the market pays for durability. | ~$133 (+52%) |
| Base (our anchor) | Estimates roughly hit — FY27E adj EPS ~$9.01; a low-growth but cash-rich compounder earns a ~12× multiple (still a discount to medtech). | ~$108 (+23%) |
| Bear | Organic growth stays stuck at ~2%, US hospital-capital softens, leverage limits buybacks; the market keeps it as a value trap. FY27E adj EPS ~$8.4; multiple stays depressed at ~9×. | ~$76 (−13%) |
Synthos fair value = the base case, ~$108 (+23%), with the full $76–$133 span as the honest range. Our base sits above the Street's $96.33 consensus because we think ~10× forward earnings under-prices the FCF and buyback, but our bear ($76) is below the Street's $83 low because the value-trap risk is real. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ZBH is neither an exponential nor an elite compounder — it is a mature, slow-growth value name:
- Forward growth: revenue CAGR FY25→FY30E ~3.8% ($8.23B → $9.92B est); adjusted-EPS CAGR FY26→FY30E ~7% ($8.49 → $11.12 est) — the EPS growth outrunning revenue is largely buyback and mix, not organic acceleration.
- Acceleration (the 2nd derivative) is roughly flat-to-negative: organic constant-currency growth was just +2.9% in Q1'26; FY26 organic guidance is 1.0–3.0%. This is a business held near GDP-plus, not one inflecting upward. Per our flagship philosophy we pick forward next-exponentials over trailing compounders — ZBH is the opposite profile.
- Room to run: the joint-replacement TAM grows with aging demographics but slowly (low-single-digits in volume, with pricing pressure). At $16.9B the stock could re-rate 1.5×, but a 3-5× multibagger would require a category and a growth rate this business does not have.
- Reinvestment runway: capex is light (~$225M, ~1.9% of revenue) and FCF is strong (~$1.47B, ~8.7% yield), but the cash goes to dividends, buybacks and debt-funded M&A (Paragon 28, Monogram) rather than an organic high-return reinvestment engine.
Exponential Potential: Low (2/10). Own ZBH — if at all — for a cheap-multiple re-rating plus buyback-driven EPS, not for growth. This honest framing is why it sits in the tactical/value sleeve, not the core or degen tiers.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $8.23B, +7.2% (FY24 $7.68B, +3.8% on FY23 $7.39B). Note the FY25 print is flattered by the Paragon 28 acquisition; organic constant-currency growth is only ~2-3%.
- Quarterly trajectory: Q1'25 $1.91B → Q2 $2.08B → Q3 $2.00B → Q4 $2.24B → Q1'26 $2.087B (+9.3% reported, but only +2.9% organic constant-currency). The reported-vs-organic gap is the whole story — M&A and FX are doing the lifting.
- Margins: gross 70.0% TTM, EBITDA margin 26.2% TTM, operating ~15.6%, net 9.1% TTM. Gross margins are healthy for devices; the low net margin reflects heavy acquisition amortization ($1.09B D&A in FY25) and interest.
- Earnings — mind the GAAP/adjusted gap: GAAP net income $705M FY25, GAAP diluted EPS $3.55. But management and the Street quote adjusted EPS, which strips ~$5 of per-share amortization/one-offs: FY25 adjusted EPS was ~$8.10–8.20 and FY26 is guided to $8.40–$8.55. Our valuation uses the adjusted basis (as the market does) but readers should know the GAAP number is far lower.
- Cash flow: operating CF $1.70B, capex ~−$225M, FCF ~$1.47B FY25 (~8.7% FCF yield). Cash conversion is the real strength here.
- Balance sheet: total debt $7.52B, net debt $6.93B, net-debt/EBITDA ~3.1× — elevated and rising (it was ~2.4× in FY24), pushed up by the Paragon 28 deal. Interest coverage ~4.4×, current ratio 1.7×. Investment-grade but leveraged; this is the constraint on capital returns.
6. Valuation — priced in or room?
ZBH is genuinely cheap on the metrics that matter for a mature cash generator: ~10.3× FY26E and ~9.7× FY27E adjusted EPS, 10.9× EV/EBITDA, 2.85× EV/sales, and an ~8.7% free-cash-flow yield with a ~1.1% dividend on top. For context, the medtech peer group typically trades 15–25× forward earnings. On a PEG basis the cheapness is more honest than spectacular — a ~10× multiple on a ~7% adjusted-EPS grower is fair-to-slightly-cheap, not a screaming bargain, which is exactly why it's a tactical call.
A simple reverse read: at $87.47 on ~$9 of FY27E adjusted EPS, the market prices ZBH at ~9.7×, i.e. it is pricing in continued low-single-digit growth and no re-rating — a low bar. If the market simply pays 12× (still a discount) for the durability and FCF, that's ~$108. Street targets (context): consensus $96.33, median $93, high $120, low $83. Our $108 base sits above consensus (we credit the FCF/buyback more than the Street) while our $76 bear undercuts the Street low (value-trap risk). Not a growth buy; a cheap-cash-flow, mean-reversion buy.
7. Technicals (from the tech block)
- Trend: down. $87.47 sits above the 50-DMA ($86.01) but below the 200-DMA ($91.83) — a weak, below-trend posture, not a confirmed uptrend.
- Location: −18.8% off the 52-week high ($107.71), +9.9% off the 52-week low ($79.58). The max drawdown from its all-time peak is −49.5% — this is a stock that has roughly halved from its highs.
- Momentum: RSI(14) 51 — dead-neutral, neither oversold nor overbought. MACD +0.48 (mildly positive, off a low base).
- Relative strength (the tell): ZBH −7.0% 12-mo vs SPY +20.6% and QQQ +30.3%; −3.9% 3-mo vs SPY +13.7%. Persistent, broad underperformance of both the market and growth — the market has been voting against this name.
- Read: technicals do not confirm the value thesis; they flag a falling knife that has stopped falling, not a turn. A value buyer should treat the neutral RSI and below-200-DMA posture as a reason to scale in on evidence of an organic-growth or margin turn, not to lump in. A reclaim of the 200-DMA (~$92) would be the first technical green light.
8. Moat & competitive position
Zimmer Biomet's moat is real but narrow: (1) surgeon switching costs and training — orthopedic surgeons are trained on specific implant systems and instrument trays and are slow to switch; (2) scale and brand in a consolidated recon market; (3) a growing robotics/data ecosystem (ROSA) that can lock in accounts. The offsets: the core knee/hip category is mature and price-pressured, and ZBH competes against larger, faster-diversifying rivals — Stryker (the robotics share-gainer with Mako), Johnson & Johnson MedTech (DePuy), and Smith & Nephew. ZBH has been a share-defender, not a share-gainer, in core recon.
Peer set (FMP-supplied; note these are broad healthcare/med-tech names, not pure orthopedic comps): Smith & Nephew $12.8B (the closest orthopedic comp), DexCom $27.5B, Illumina $28.5B, Waters $24.7B, West Pharmaceutical $25.8B, STERIS $21.3B, United Therapeutics $23.6B, Labcorp $23.5B, Quest Diagnostics $23.9B, Incyte $23.3B. ZBH ($16.9B) trades at a lower multiple than most of this group — the discount reflects its slower growth, not a hidden bargain the market missed. Its true head-to-head rivals (Stryker, J&J) are not in this list.
9. Management, capital allocation & guidance
- Capital allocation: balanced but leverage-constrained — a growing dividend (~1.1% yield, ~25% payout), steady buybacks ($250M in Q1'26; $487M in FY25), and debt-funded M&A (Paragon 28 in 2025, Monogram robotics) that pushed net-debt/EBITDA to ~3.1×. The M&A is a deliberate bet to buy growth the core business doesn't generate organically — sensible in theory, but it is why leverage is elevated and why reported growth overstates organic.
- Insider activity: the recent Form 4s are almost entirely routine director equity awards (phantom stock units at $86.65 on 2026-06-30) — not open-market buying. One officer open-market sale (Group President, Asia Pacific, 4,200 shares at $82.64 on 2026-05-29). Nothing alarming, but no conviction insider buying to corroborate the value thesis either.
- Management's own guidance (half-weighted — their book): ZBH's Q1'26 earnings release (SEC 8-K, filed 2026-04-28) is a genuine release and raised full-year 2026 adjusted EPS guidance to $8.40–$8.55 (from $8.30–$8.45) and lifted free-cash-flow expectations. Full-year reported revenue growth guided 2.5–4.5%, organic constant-currency just 1.0–3.0% — management's own numbers confirm the low-single-digit organic reality. CEO Ivan Tornos framed it as "healthy end markets… disciplined execution… consistent, durable growth over the longer term." We half-weight this (management talks its own book), but the raised EPS/FCF guide is a mild positive and the organic guide is an honest tell on the growth ceiling.
10. Catalysts & what to watch
- Next earnings: 2026-08-06 (Q2'26; Street adj EPS $2.01, revenue ~$2.14B). The key line: organic constant-currency growth — does it hold above ~2-3%, and does S.E.T./robotics momentum offset flat core recon?
- Organic growth inflection: the single biggest swing factor. Two+ quarters of organic growth accelerating toward mid-single-digits would justify the bull re-rating; stalling at ~2% confirms the value trap.
- Robotics traction (ROSA / Monogram): pull-through on implants and account wins vs Stryker's Mako.
- De-leveraging: net-debt/EBITDA trending back toward ~2.5× would free up buybacks and de-risk the balance sheet.
- US hospital capital & elective-procedure volumes: the demand cycle for elective joint replacement.
Thesis tripwires (what would change the call): organic constant-currency growth falling below ~1% for two quarters; net-debt/EBITDA rising above ~3.5×; a cut to adjusted-EPS or FCF guidance; or ROSA/robotics losing share to Mako.
11. Key risks
- Slow-growth / value-trap risk (structural): ~2-3% organic growth in a mature, price-pressured category means the stock can stay cheap indefinitely if no re-rating catalyst arrives. This is the central risk.
- Leverage: 3.1× net-debt/EBITDA is elevated for a slow grower; it constrains buybacks and magnifies any earnings stumble. Rising rates or a soft cycle bite harder here.
- Competitive share loss: Stryker's robotics-led momentum and J&J's scale threaten ZBH's core knee/hip franchise.
- GAAP/adjusted gap: the market values ZBH on adjusted EPS (~$8.5) that is ~2.4× reported GAAP EPS (~$3.55); heavy amortization means reported returns on capital are low (ROE ~6%, ROIC ~5%).
- Cyclicality & reimbursement: elective-procedure volumes and US hospital budgets are cyclical; device pricing faces continuous payer pressure.
- No expert corroboration: unlike a conviction name, there is zero independent expert breadth in the Synthos KB supporting this call — it rests entirely on the quant/value read, which is a risk in itself.
12. Verdict, position sizing & monitoring
Buy — Tactical. ZBH is a cheap (~10× forward adjusted EPS, ~8.7% FCF yield), low-beta, cash-generative orthopedic leader trading ~19% below its 52-week high and ~50% below its all-time peak, with a fresh raised FY26 adjusted-EPS/FCF guide. Our base-case fair value of ~$108 (+23%) says the market under-prices the durability and buyback. But this is explicitly a value/mean-reversion trade, not a compounder to own for a decade: growth is stuck in the low single digits, leverage is elevated, the technicals are below-trend, and — critically — there is no expert conviction in the Synthos KB to corroborate the call.
- Sizing: satellite value/tactical, ~1–3% — smaller than a conviction position, with a hard leverage-and-organic-growth tripwire. Scale in on evidence (an organic-growth turn or a 200-DMA reclaim), don't lump in against a downtrend.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $87.47.
- Single biggest risk: the value trap — ~2-3% organic growth plus 3.1× leverage means the discount could persist unless growth re-accelerates or the balance sheet de-levers.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — Zimmer Biomet has no expert coverage in the Synthos knowledge base. Per house standard, no conviction was fabricated; the verdict is fundamentals- and quant-driven. Any claim of expert conviction here would be structurally impossible (claim-ID reconciliation) — and there are none to cite.
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates; EPS figures are the adjusted/non-GAAP basis on which the stock is quoted and guided, unless noted as GAAP.
- Management caveat: ZBH's raised FY26 guidance is management's own book, half-weighted by design; the organic 1-3% guide is treated as the honest growth tell.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").